Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors represent the standard of
care in patients with EGFR mutation-positive (EGFR m+) non-small cell lung cancer …
care in patients with EGFR mutation-positive (EGFR m+) non-small cell lung cancer …
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised …
K Park, EH Tan, K O'Byrne, L Zhang, M Boyer… - The Lancet …, 2016 - thelancet.com
Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …
[HTML][HTML] Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation …
M Kimura, F Yasue, E Usami… - Molecular and …, 2018 - spandidos-publications.com
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib,
erlotinib and afatinib are standard first-line treatments for EGFR gene mutation-positive non …
erlotinib and afatinib are standard first-line treatments for EGFR gene mutation-positive non …
[HTML][HTML] Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene …
P Krawczyk, DM Kowalski, R Ramlau… - Oncology …, 2017 - spandidos-publications.com
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are routinely used
to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of …
to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of …
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors
L Landi, M Tiseo, R Chiari, S Ricciardi, E Rossi… - Clinical lung cancer, 2014 - Elsevier
Background The purpose of this study was to evaluate the efficacy of afatinib in EGFR-
mutant metastatic NSCLC patients with acquired resistance to erlotinib or gefitinib. Materials …
mutant metastatic NSCLC patients with acquired resistance to erlotinib or gefitinib. Materials …
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
V Nelson, J Ziehr, M Agulnik… - OncoTargets and therapy, 2013 - Taylor & Francis
The discovery of epidermal growth-factor receptor (EGFR)-activating mutations and the
introduction of oral EGFR tyrosine kinase inhibitors (EGFR-TKIs) have expanded the …
introduction of oral EGFR tyrosine kinase inhibitors (EGFR-TKIs) have expanded the …
Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review
J Köhler, M Schuler - Onkologie, 2013 - karger.com
Non-small cell lung cancer (NSCLC) consists of several histomorphologically defined
phenotypes that display an enormous genetic variability. In recent years, epidermal growth …
phenotypes that display an enormous genetic variability. In recent years, epidermal growth …
Afatinib in the treatment of EGFR mutation-positive NSCLC–a network meta-analysis
Objectives Epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung
cancer (NSCLC) is a specific lung cancer subtype characterized by sensitivity to treatment …
cancer (NSCLC) is a specific lung cancer subtype characterized by sensitivity to treatment …
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors
DF Heigener, C Schumann, M Sebastian… - The …, 2015 - academic.oup.com
Abstract Background. Afatinib, an irreversible ErbB family blocker, is approved for treatment
of patients with previously untreated non-small cell lung cancer (NSCLC) harboring …
of patients with previously untreated non-small cell lung cancer (NSCLC) harboring …
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
K Park, D Wan-Teck Lim, I Okamoto… - … advances in medical …, 2019 - journals.sagepub.com
Afatinib is an ErbB family blocker that is approved for the treatment of epidermal growth
factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pivotal …
factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pivotal …